Breast Cancer Patients Take DNA Test to Determine Best Treatment
Posted on: Thursday, 30 October 2008, 12:00 CDT
SEATTLE, Oct. 30 /PRNewswire/ -- Nearly one third of breast cancer patients prescribed tamoxifen currently fail treatment. According to the National Foundation for Cancer Research (NFCR), this failure rate can be reduced to less than ten percent, saving 20,000 lives each year, by having patients take a simple DNA test and properly managing their medications.
Recent research shows that tamoxifen has to be activated into endoxifen by the liver enzyme CYP2D6. Endoxifen is the medicine that prevents the recurrence of estrogen receptive positive cancers.
About ten percent of breast cancer patients prescribed tamoxifen are missing CYP2D6 because of their DNA, and will fail tamoxifen treatment. "Patients want to know that tamoxifen will definitely benefit them, before committing to take it for five years. DNA testing offers them the reassurance that their tamoxifen is effective," stated Dr. Michael Benjamin, oncologist and editor of the medical news website, InteractMD.com
Breast cancer patients can also fail tamoxifen treatment by unknowingly taking other prescription drugs, herbals preparations, or over-the-counter medicines that interfere with CYP2D6 activity. Many classes of drugs, including anti-depressants, prevent CYP2D6 from converting tamoxifen into endoxifen. That's why Genelex includes password-protected access to their GeneMedRx software program with each test. Patients enter all of the drugs they take and produce a report to learn if any of the drugs they take might be defeating their endoxifen treatment.
"Patients and physicians need to be aware that DNA testing for tamoxifen effectiveness is available now. There is typically a 10-year gap between research and application in the clinical setting. We need to shorten that time when people's lives are at stake -- as they are with tamoxifen," stated Genelex founder and CEO Howard Coleman.
For more information about the CYP2D6 DNA test, visit Genelex at http://www.healthanddna.com/, or call (800) 532-3080. Genelex donates a portion of all tests purchased to the National Foundation for Cancer Research.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Howard Coleman
http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=44528
Genelex Corporation
CONTACT: Howard Coleman, CEO of Genelex Corporation, +1-206-826-1970
Web Site: http://www.genelex.com/http://www.healthanddna.com/
Source: PRNewswire
Related Articles
- Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report
- Growing Number of Consumers Trust Online Resources Over Other Media for Researching Drug Treatment Information -- Prospectiv Survey Reveals
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- Consumers Researching Drug Treatment Information Online Turn First to General Health-Focused Sites, Followed By Sites Dedicated to Specific Ailments -- Prospectiv Survey Reveals
- Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- Seventy-Eight Percent of Newly Diagnosed Dyslipidemia Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- Bionovo's Publication Tagged As 'Critical Trial' By Leading Journal: Breast Cancer Research and Treatment
- Research and Markets: Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development
- Advances in Single-Patient Trials for Drug Treatment Optimization and Risk Management*
- Tamoxifen Raises Endometrial Cancer Risk
 |
 |
User Comments (0)
RSS Feeds